Impact of highly active antiretroviral therapy on anemia and relationship between anemia and survival in a large cohort of HIV-infected women: Women's interagency HIV study

Journal of Acquired Immune Deficiency Syndromes

Volumn 37, Issue 2, 2004, Pages 1245-1252

  Berhane, Kiros ^a   Karim, Roksana ^a   Cohen, Mardge H ^b   Masri Lavine, Lena ^a   Young, Mary ^c   Anastos, Kathryn ^d   Augenbraun, Michael ^e   Watts, D Heather ^f   Levine, Alexandra M ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Jr Hospital of Cook County   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

^d MONTEFIORE MEDICAL CENTER   (United States)

^e MAIMONIDES MEDICAL CENTER   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

AIDS; Anemia; HIV; Survival; Women

Indexed keywords

ABACAVIR; CD4 ANTIGEN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANAMNESIS; ANEMIA; ARTICLE; CELL COUNT; CLINICAL STUDY; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; ETHNOLOGY; FEMALE; FOLLOW UP; HEMOGLOBIN DETERMINATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MONOTHERAPY; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RACE; RISK FACTOR; SURVIVAL;

ADOLESCENT; ADULT; AGED; ANEMIA; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MIDDLE AGED; MULTICENTER STUDIES; RNA, VIRAL; SURVIVAL RATE;

EID: 4644295283     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000134759.01684.27     Document Type: Article

References (42)

1. Zon LI, Arkin C, Groopman JE. Hematologic manifestations of the human immunodeficiency virus (HIV). Semin Hematol. 1988;25:208-219.
2. Levine AM. Anemia, neutropenia and thrombocytopenia: pathogenesis and evolving treatment options in HIV infected patients. In: King E, ed. HIV Clinical Management. vol. 10. New York, NY: Medscape/WebMD; 2002. Available at: www.medscape.com.
3. Sullivan PS, Hanson D, Chu SY, et al. Epidemiology of anemia in human immunodeficiency virus infected persons: results from the Multistate Adult and Adolescent Spectrum of HIV Disease Surveillance Project. Blood. 1998;91:301-308.
4. Abrams DI, Steinhart C, Frascino R. Epoetin alfa therapy for anaemia in HIV infected patients: impact on quality of life. Int J STD AIDS. 2000;11:659-665.
5. Moore RD, Keruly JC, Chaisson RE. Anemia and survival in HIV infection. J Acquir Immune Defic Syndr. 1998;19:29-33.
6. Moore RD. Human immunodeficiency virus infection, anemia, and survival. Clin Infect Dis. 1999;29:44-49.
7. Mocroft A, Kirk O, Barton SE, et al. Anemia is an independent predictive marker for clinical prognosis in HIV infected patients from across Europe. AIDS. 1999;13:943-950.
8. Lundgren JD, Mocroft A, Gatell JM, et al. A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study. J Infect Dis. 2002;185:178-187.
9. Semba RD, Shah N, Klein S, et al. Prevalence and cumulative incidence of and risk factors for anemia in a multicenter cohort study of human immunodeficiency virus-infected and -uninfected women. Clin Infect Dis. 2002;34:260-266.
10. Levine AM, Berhane K, Masri-Lavine L, et al. Prevalence and correlates of anemia in a large cohort of HIV infected women. Women's Interagency HIV Study. J Acquir Immune Defic Syndr. 2001;26:28-35.
11. Ledergerber B, Egger M, Erard V, et al. AIDS related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA. 1999;282:2220-2226.
12. Lee LM, Karon JM, Selik R, et al. Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984-1997. JAMA. 2001;285:1308-1315.
13. Gange SJ, Barron Y, Greenblatt RM, et al. The Women's Interagency HIV Study Collaborative Study Group: effectiveness of highly active antiretroviral therapy among HIV-1 infected women. J Epidemiol Community Health. 2002;56:153-159.
14. Carpenter CCJ, Cooper DA, Fischel MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2000;283:381-390.
15. Sloand EM, Maciejewski J, Kumar P, et al. Protease inhibitors stimulate hematopoiesis and decrease apoptosis and ICE expression in CD34+ cells. Blood. 2000;96:2735-2739.
16. Huang SS, Barbour JD, Decks SG, et al. Reversal of human immunodeficiency virus type 1-associated hematosuppression by effective antiretroviral therapy. Clin Infect Dis. 2000;30:504-510.
17. Barkan SE, Melnick S, Preston-Martin S, et al. The Women's Interagency HIV Study. Epidemiology. 1998;9:117-125.
18. Petersdorf RG, Adams RD, Braunwald E, et al, eds. Harrison's laboratory values of clinical importance. In: Principles of Internal Medicine. 10th ed. New York: McGraw-Hill; 1983:A-3.
19. DHHS/Henry J. Kaiser Family Foundation Panel on Clinical Practices for the Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV infected adults and adolescents, January 2000 revision. Available at: http://hivatis.org. Accessed October 11, 2000.
20. Kleinbaum DG, Kupper LL, Muller KE, et al. Applied Regression Analysis and Other Multivariable Methods. 3rd ed. Pacific Grove, CA: Duxbury Press; 1998.
21. Diggle PJ, Liang K-Y, Zeger SL. Analysis of Longitudinal Data. New York: Oxford University Press; 1994.
22. Agresti A. Categorical Data Analysis. New York: John Wiley; 1990.
23. Hessol NA, Schneider M, Greenblatt RM, et al. Retention of women enrolled in a prospective study of human immunodeficiency virus infection: impact of race, unstable housing, and use of human immunodeficiency virus therapy. Am J Epidemiol. 2001;154:563-573.
24. Cox DR, Oakes D. Analysis of Survival Data. London: Chapman and Hall; 1984.
25. Cox DR. Regression models and life tables (with discussion). J R Stat Soc [Ser B]. 2001;34:187-220.
26. Littlewood TJ, Bajetta E, Nortier JWR, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001;19:2865-2874.
27. Albain KS, Crowley JJ, LeBlanc M, et al. Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience. J Clin Oncol. 1991;9:1618-1626.
28. Ohlhauser C, Bulzebruck H, Ebert W, et al. Prognostic factors for survival in inoperable non-small-cell lung cancer: a multivariate regression analysis of 456 patients with radiation therapy. Oncology. 1997;20:126-131.
29. Anastos K, Barron Y, Miotti P, et al. Risk of progression to AIDS and death in women infected with HIV-1 initiating highly active antiretroviral treatment at different stages of disease. Arch Intern Med. 2002;162:1973-1980.
30. Moore RD, Forney D. Anemia in HIV infected patients receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;29:54-57.
31. Ahdieh L, Gange SJ, Greenblatt R, et al. Selection by indication of potent antiretroviral therapy use in a large cohort of women infected with human immunodeficiency virus. Am J Epidemiol. 2000;152:923-933.
32. Koka PS, Jamieson BD, Brooks DG, et al. HIV-1 induced hematopoietic inhibition is independent of productive infection of progenitor cells in vivo. J Virol. 1999;73:9089-9097.
33. Moses AU, Williams S, Henevild ML, et al. Human immunodeficiency virus infection of bone marrow endothelium reduces induction of stromal hematopoietic growth factors. Blood. 1996;87:919-925.
34. Bahner I, Kerans K, Coutinho S, et al. Infection of human marrow stroma by HIV-1 is both required and sufficient for HIV-1 induced hematopoietic suppression in vitro: demonstration by gene modification of primary human stroma. Blood. 1997;90:1787-1798.
35. Scadden DT, Zeira M, Woon A, et al. Human immunodeficiency virus infection of human bone marrow stromal fibroblasts. Blood. 1990;76:317-322.
36. Spivak JL, Barnes DC, Fuchs E, et al. Serum immunoreactive erythropoietinin HIV infected patients. JAMA. 1989;261:3104-3107.
37. Sipsas NV, Kokori SI, Ionnidis JPA, et al. Circulating autoantibodies to erythropoietin are associated with human immunodeficiency virus type I related anemia. J Infect Dis. 1999;180:2044-2047.
38. Frickhofen N, Abkowitz JL, Safford M, et al. Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1: a treatable cause of anemia in AIDS. Ann Intern Med. 1990;113:926-933.
39. Seneviratne LC, Tulpule A, Espina BM, et al. Clinical, immunologic, and pathologic correlates of bone marrow involvement in 291 patients with AIDS related lymphoma. Blood. 2001;98:2358-2363.
40. Walker RE, Parker RI, Kovacs JA, et al. Anemia and erythropoiesis in patients with the acquired immunodeficiency syndrome (AIDS) and Kaposi's sarcoma treated with zidovudine. Ann Intern Med. 1988;108:372-376.
41. Semba RD, Shah N, Vlahov D. Improvement of anemia among HIV infected injection drug users receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;26:315-319.
42. Isgro A, Mezzaroma I, Aiuti A, et al. Recovery of hematopoietic activity in bone marrow from human immunodeficiency virus type 1 infected patients during highly active anti-retroviral therapy. AIDS Res Hum Retroviruses. 2000;16:1471-1479.